A Four-Year Appraisal of Thioridazine
Abstract
A four-year survey of the use of thioridazine is reported. A high success rate was obtained in a variety of mental disorders encountered in 1,225 psychiatric patients, both hospitalized and outpatient.
The results obtained in the largest group, the schizophrenics, were especially striking. The capacity of thioridazine to suppress the symptoms of schizophrenia was reflected in the prototype of a calm, obedient, well-behaved, and manageable patient.
In mental defectives, with and without epilepsy, thioridazine proved to be effective in behavioral problems. Freedom from excessive sedation or obtunding effect made it especially valuable in remotivating outpatients and facilitating their adaptation to the outside world.
Results obtained with thioridazine show it to be highly effective, well tolerated, and consistent in its therapeutic action.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
